ProCE Banner Activity

Panel Discussion: New and Novel Advances in AML Therapeutics

Slideset Download
Download these slides from a live webinar where 2 experts discuss novel emerging therapies in the treatment of AML

Released: July 28, 2022

Expiration: July 27, 2023

Share

Faculty

Naval G. Daver

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amir Fathi

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Genentech, a member of the Roche Group

Jazz Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval G. Daver, MD: consultant/advisor/speaker: AbbVie, Agios, Amgen, Arog, Astellas, Bristol-Myers Squibb, Celgene, Daiichi-Sankyo, Genentech, Gilead Sciences, Jazz, Novartis, Pfizer, Servier, Shattuck Labs, Syndax, Trillium; researcher: AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead Sciences, Glycomimetics, Hanmi, ImmunoGen, Novimmune, Pfizer, Trillium, Trovagene; independent contractor: ImmunoGen.

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Amir T. Fathi, MD: consultant/advisor/speaker: AbbVie, Agios, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Enclear, Foghorn, Forma, Genentech, Immunogen, Ipsen, Kite, Mablytics, Morphosys, Novartis, Orum, PureTech, Servier, Takeda